BIAF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BioAffinity Technologies Inc (BIAF) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available. The lack of positive trading signals, weak financial performance, and absence of significant catalysts make it prudent to hold off on investing in this stock right now.
The MACD is above 0 but positively contracting, indicating weakening momentum. RSI is neutral at 48.882, showing no clear overbought or oversold condition. Moving averages are converging, suggesting indecision in price trends. Key support is at 0.96, and resistance is at 1.31. The stock has a 40% chance to decline slightly in the next day and week, with a potential 9.77% gain in the next month.
NULL identified. No recent news or significant trading trends from hedge funds or insiders. Congress trading data is also unavailable.
The stock price dropped 5.31% in the regular market session, with an additional 1.99% decline in pre-market. Broader market sentiment is negative with the S&P 500 down 1.52%. Financial performance is weak, with revenue down 38.48% YoY and EPS declining.
In Q3 2025, revenue dropped 38.48% YoY to $1,446,066. Net income improved but remains negative at -$5,051,084, up 152.45% YoY. EPS fell 2.07% YoY to -4.74. Gross margin also declined 16.38% YoY to 27%. Overall, the company is underperforming financially.
No analyst rating or price target data available.
